A panel of experts have recommended that the Ministry of Food and Drug Safety grant conditional use authorization to the South Korean pharmaceutical giant Celltrion for its COVID-19 treatment candidate.
That'll enable the drug to be used more generally in South Korea and to export it to other countries.
Celltrion is working on a monoclonal antibody treatment called CT-P59, also known as Regdanvimab.
The ministry said Monday it was advised to give the go-ahead on the condition that the drug goes through another, third trial.
Clinical data so far show the drug can shorten COVID-19 recovery times by almost 3-and-a-half days.
But in terms of how long it takes to test negative, it did not show any significant effect.